ProTrials Named One of the Fastest-Growing Companies and a Top Women-Owned Business
Mountain View, CA
ProTrials Research Inc., announced that it has earned a spot for the third consecutive year on Inc. Magazine’s Inc. 5000, an exclusive list of the fastest growing private companies in the U.S., and the Silicon Valley/San Jose Business Journal’s top women-owned businesses, a list of the largest public and private Silicon Valley women-owned businesses. The contract research organization (CRO) achieved these rankings based on revenue figures.
Inc. 5000 companies are chosen based on company’s year over year revenue growth for the past three years. To be considered, companies must be U.S.-based and privately held, for profit and independent – not subsidiaries or divisions of other companies. The 5000 companies that made the list reported aggregate revenue of $214 billion and median three-year growth of 126 percent.
The Silicon Valley/San Jose Business Journal list of the top 25 women-owned businesses ranks area public and private women-owned companies according to revenue.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
